ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 403

High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting

Juliana Brunelli1, Ana Renata Schmidt1, Adriana M E Sallum2, Cláudia Goldenstein-Schainberg3, Eloisa Bonfa4, Clovis A Silva5 and Nadia E Aikawa6, 1Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, 2Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, 3Rheumatology Division, University of São Paulo, São Paulo, Brazil, 4Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 5Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 6Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic drugs, Infection, Juvenile idiopathic arthritis (JIA) and opportunistic infections

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have not focused on risk factors for this condition. In addition, previous publications of biological therapies were performed in distinct settings regarding endemic area and infection surveillance protocol. Therefore, our objectives were to assess the rate of serious/opportunistic infections in JIA patients from a single tertiary center under biologic therapy using a standardized electronic protocol in order to identify possible risk factors associated to theses complications.

Methods: From August 2004 to March 2016, 107 consecutive JIA patients were longitudinally followed at the biologic therapy center of the Rheumatology Division of our tertiary university hospital using a standardized electronic database protocol including demographic data, clinical and laboratorial findings and treatment at baseline and at the moment of infection. Serious infections were defined as those requiring hospitalization or intravenous antibiotics and opportunistic infections included tuberculosis(TB), herpes zoster(HZ) and systemic mycosis. All subcutaneous and intravenous biologic agents are regularly administered in our center with previous infectious screening.

Results: The mean age at baseline was 14.6±5.7yrs, 71% were females and median disease duration prior to biologic therapy was 4.8yrs (0.1-21). A total of 398 patient-yrs (py) were included: 179py for etanercept (ETN), 92py for adalimumab (ADA), 22py for infliximab (IFX), 78py for abatacept (ABA) and 27py for tocilizumab (TCZ). The median time of biologic exposure was 3.0 years (0.15-11.5). We observed 35 serious/opportunistic infectious events in 27 (25%) patients:31 (88.6%) were serious infections and 7 (20%) opportunistic (1 TB, 5 HZ, 1 systemic candidiasis). The median time of total biologic exposure until infection was 18 months (1–91) and most common sites were: 34% skin/soft tissue, 23% urinary tract and 20% respiratory tract. No patient died due to infectious complications. Serious/opportunistic infections rates were 10.6/100py for ETN, 10.9/100py for ADA, 2.6/100py for ABA and 14.8/100py for TCZ. Comparison of 27 patients with and 80 without infection showed a higher frequency of systemic-onset JIA (44 vs. 20%,p=0.021), lower age at biologic therapy initiation (12 ± 6 vs. 16 ± 5yrs,p=0.005) and a history of previous serious infection (33 vs. 14%,p=0.042) in the former group. Further analysis of 35 patients with and 80 patients without infectious complications balanced for mean time of biologic exposure revealed a significantly higher frequency of lymphopenia (17 vs. 1%,p=0.003) during infection events. Disease activity parameters and concomitant treatment had no influence on infections rate (p>0.05).

Conclusion: This single center study demonstrated a high rate of serious infections in JIA patients under biologic therapy in a real life setting, except for ABA. Systemic-onset JIA, lower age at biologic therapy start, history of previous serious infections and lymphopenia were important risk factors for these complications.


Disclosure: J. Brunelli, None; A. R. Schmidt, None; A. M. E. Sallum, None; C. Goldenstein-Schainberg, None; E. Bonfa, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2009/51897-5), 2; C. A. Silva, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2009/51897-5), 2; N. E. Aikawa, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2009/51897-5), 2.

To cite this abstract in AMA style:

Brunelli J, Schmidt AR, Sallum AME, Goldenstein-Schainberg C, Bonfa E, Silva CA, Aikawa NE. High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/high-rate-of-serious-infection-in-juvenile-idiopathic-arthritis-under-biologic-therapy-in-a-real-life-setting/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-rate-of-serious-infection-in-juvenile-idiopathic-arthritis-under-biologic-therapy-in-a-real-life-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology